Scarica l'app Stockscreener
1.67
5.70%
0.09
Dopo l'orario di chiusura:
1.70
0.03
+1.80%
Precedente Chiudi:
$1.58
Aprire:
$1.56
Volume 24 ore:
2.00M
Relative Volume:
0.44
Capitalizzazione di mercato:
$142.23M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.2014
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
-3.47%
1M Prestazione:
-8.24%
6M Prestazione:
-2.91%
1 anno Prestazione:
-9.24%
Intervallo 1D:
$1.53
$1.67
Intervallo di 1 settimana:
$1.53
$1.70
Portata 52W:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.67 | 134.57M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-09-11 | Iniziato | Wells Fargo | Overweight |
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Stock Report: Does Milestone Pharmaceuticals Inc have consistent dividend growthRecession Risk & Safe Entry Point Alerts - baoquankhu1.vn
Earnings Report: Should I invest in Milestone Pharmaceuticals Inc before earningsShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC - MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday - MarketBeat
MIST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trend Review: Can Milestone Pharmaceuticals Inc beat the S P 500Earnings Growth Report & Expert Curated Trade Setups - baoquankhu1.vn
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
Aug Outlook: Can Milestone Pharmaceuticals Inc beat the S P 500Portfolio Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Zacks Research Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold - MarketBeat
BlackRock HPS Credit Strategies Fund's Milestone Pharmaceuticals Inc(MIST) Holding History - GuruFocus
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Does Milestone Pharmaceuticals Inc. have consistent dividend growthQuarterly Investment Review & AI Powered Buy and Sell Recommendations - mfd.ru
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Milestone Pharmaceuticals - WCIV
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
MIST Should I Buy - Intellectia AI
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Appoints David Sandoval As General Counsel And Chief Compliance Officer - TradingView
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) CFO updates 204,000-share option to $1.96 - Stock Titan
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 133,054 Shares - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Milestone Pharmaceuticals announces U.S. availability of cardamyst - Yahoo Finance
Milestone’s PSVT treatment CARDAMYST now available in US pharmacies By Investing.com - Investing.com Canada
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies - TipRanks
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):